Soft Q1 revenue miss; export weakness offset by domestic volume and biologicals growth

Domestic 3% revenue on 12% volume indicates ~8% pricing erosion; volume claim supported

No segment breakout in financials, but call commentary consistent with high-growth niche positioning

Q1 gross margin 57% delivered; EBITDA margin 22% (vs 22% prior, flat)

Disclosed explicitly; analyst questioned 13% rupee depreciation benefit not flowing through

Still awaiting regulatory approval; not launched in Q1; timeline remains 'hoped for' not confirmed

Prior: 'positive revenue growth' for FY27. Call: 'lower single-digit growth, depends on cycle.' Q1 -10.4% YoY confirms slow start; H2 must accelerate significantly.

Prior call said 'recovery in H2 FY26 would set up FY27 growth.' Now: H2 FY27 recovery expected. Weakness persisted longer than initially flagged.

Prior: expected scaling. Now: ~₹100Cr EBITDA loss this quarter from global biologicals (market dev, field trials, geographies), confirming heavy front-loading for 5-10 year payoff.

Prior: building CRDMO capabilities. Now: detailed that pharma is early-stage, order book delays into Q2 expected, portfolio small, breakeven 'years away' (not quantified).

Majority Agchem in R&D, CSM, development funnels. NCE pipeline strong. Biologicals 2 launched, 2-3 in pipeline. Electronics larger portfolio but different value props. 4-5 launches FY27 (mostly Agchem, 2 Electronics, 1-2 Pharma/Health Sciences).

Demand cycle challenged, commodity prices flat, input costs high. Generics bear full brunt; differentiated products less exposed. Hoping cycle breaks this year.

Positive trajectory, lower single-digit as indicated earlier. Depends on cycle/industry, could go either way.

Not straightforward given geopolitical, commodity, logistics volatility. Objective is sustain gross margins via optimization. Challenges likely but approach is agile.

Early start this year, hoping within the year for India pending regulatory approval. Other geographies: one next year, one year after.

Pass-through model of value proposition. Currency benefits shared with customers; also currency risk management in play. Business about products/margins, not FX.

Not in molecules; in CRDMO services. Long gestation model. Upfront regulatory investment required. Portfolio still small; scale will reduce volatility.

Not benchmarking to CTPR; different value props. Better efficacy in certain pests. 5-decade partnership with global innovator; confident on co-creation.

Our approach: market share via differentiated products, not price escalation. Generics saw inflation; we positioned premium.

Global Biologicals and other new initiatives. Heavy market dev spending (1000 farmer interactions, 500 demos across Brazil/Mexico/US). Good losses = future revenue.

R&D is value creation, not loss. Global benchmark: innovators invest 3-5%. We at 3-4% of revenue, sustainable. Biologicals/Pharma need time to scale.

Global biologicals $10B. Brazil nematicide $750M, 5M hectares tested last season. India/US: newer concept, significant opportunity.

Long gestation, entered nascent. Now commercial plant operational, supplies started with new tech. Aiming billion-dollar play, investing in high-tech asset.

Double-digit market share is not a challenge. Takes 5-10 years to develop such products.

Launching this season. Three-digit revenue potential in Indian context over 5-7 years, similar to large molecules.

Conditional on H2 export recovery and new product launches (Pioxaniliprole NCE, 4-5 molecules). Macro-dependent on commodity cycle, monsoon, geopolitics. Q1 -10.4% YoY requires strong H2.

Q1 delivered 57%. Input cost and pricing pressure offset by optimization and portfolio management.

R&D at 3-4% of revenue ongoing. Pharma/Biologicals EBITDA losses expected to persist 2-3 years as long-gestation platforms.

Q1 at ~₹250Cr pace on track. Flow chemistry plant, CRDMO facilities, biologicals scale-up investments ongoing.

Exports volume -8%, value -12%. Domestic pricing decline ~8% on 12% volume. Commodity cycle may extend beyond H2 FY27, delaying recovery targets.

Export value -12% despite -8% volume and 13% rupee depreciation. Pass-through model shares FX benefits with customers, limiting upside from currency movements.

Pharma -₹60Cr EBITDA, Biologicals -₹100Cr/quarter. R&D 3-4% of revenue (~₹60-70Cr annually). Breakeven timelines vague; 5-10 year payoff assumptions may not hold under slower growth.

Pioxaniliprole awaiting domestic regulatory approval. Launch 'hoped for within the year' but not guaranteed. Global registrations staggered (next year, year after). Delays push revenue to FY28.

Domestic 12% volume but 3% revenue implies 8% pricing erosion. Exports similarly pressured. Differentiated products help, but pricing power uncertain in prolonged soft market.